Aditya J Ullal1, Claire T Than2, Jun Fan2, Susan Schmitt2, Alexander C Perino2, Daniel W Kaiser3, Paul A Heidenreich1, Susan M Frayne1, Ciaran S Phibbs1, Mintu P Turakhia4. 1. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Stanford University School of Medicine, Stanford, CA. 2. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA. 3. Stanford University School of Medicine, Stanford, CA. 4. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Stanford University School of Medicine, Stanford, CA. Electronic address: mintu@stanford.edu.
Abstract
BACKGROUND: There are limited data on mortality outcomes associated with use of amiodarone in atrial fibrillation and flutter (AF). METHODS: We evaluated the association of amiodarone use with mortality in patients with newly diagnosed AF using complete data from the Department of Veterans Affairs national health care system. We included patients seen in an outpatient setting within 90 days of a new diagnosis for nonvalvular AF between Veterans Affairs fiscal years 2004 and 2008. Multivariate analysis and propensity-matched Cox proportional hazards regression were used to evaluate the association of amiodarone use to death. RESULTS: Of 122,465 patients (353,168 person-years of follow-up, age 72.1 ± 10.3 years, 98.4% males), amiodarone was prescribed in 11,655 (9.5%). Cumulative, unadjusted mortality rates were higher for amiodarone recipients than for nonrecipients (87 vs 73 per 1,000 person-years, P < .001). However, in multivariate and propensity-matched survival analyses, there was no significant difference in mortality (multivariate hazard ratio 1.01, 95% CI 0.97-1.05, P = .51, and propensity-matched hazard ratio 1.02, 95% CI 0.97-1.07, P = .45). The hazard of death was not modified by age, sex, heart failure, kidney function, β-blocker use, or warfarin use, but there was evidence of effect modification among patients diagnosed with AF as an inpatient versus outpatient. CONCLUSION: In a national health care system population of newly diagnosed AF, overall use of amiodarone as an early treatment strategy was not associated with mortality. Published by Elsevier Inc.
BACKGROUND: There are limited data on mortality outcomes associated with use of amiodarone in atrial fibrillation and flutter (AF). METHODS: We evaluated the association of amiodarone use with mortality in patients with newly diagnosed AF using complete data from the Department of Veterans Affairs national health care system. We included patients seen in an outpatient setting within 90 days of a new diagnosis for nonvalvular AF between Veterans Affairs fiscal years 2004 and 2008. Multivariate analysis and propensity-matched Cox proportional hazards regression were used to evaluate the association of amiodarone use to death. RESULTS: Of 122,465 patients (353,168 person-years of follow-up, age 72.1 ± 10.3 years, 98.4% males), amiodarone was prescribed in 11,655 (9.5%). Cumulative, unadjusted mortality rates were higher for amiodarone recipients than for nonrecipients (87 vs 73 per 1,000 person-years, P < .001). However, in multivariate and propensity-matched survival analyses, there was no significant difference in mortality (multivariate hazard ratio 1.01, 95% CI 0.97-1.05, P = .51, and propensity-matched hazard ratio 1.02, 95% CI 0.97-1.07, P = .45). The hazard of death was not modified by age, sex, heart failure, kidney function, β-blocker use, or warfarin use, but there was evidence of effect modification among patients diagnosed with AF as an inpatient versus outpatient. CONCLUSION: In a national health care system population of newly diagnosed AF, overall use of amiodarone as an early treatment strategy was not associated with mortality. Published by Elsevier Inc.
Authors: Sanjeev Saksena; April Slee; Albert L Waldo; Nick Freemantle; Mathew Reynolds; Yves Rosenberg; Snehal Rathod; Shannon Grant; Elizabeth Thomas; D George Wyse Journal: J Am Coll Cardiol Date: 2011-11-01 Impact factor: 24.094
Authors: Bramah N Singh; Steven N Singh; Domenic J Reda; X Charlene Tang; Becky Lopez; Crystal L Harris; Ross D Fletcher; Satish C Sharma; J Edwin Atwood; Alan K Jacobson; H Daniel Lewis; Dennis W Raisch; Michael D Ezekowitz Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Jonathan S Steinberg; Ara Sadaniantz; Jack Kron; Andrew Krahn; D Marty Denny; James Daubert; W Barton Campbell; Edward Havranek; Katherine Murray; Brian Olshansky; Gearoid O'Neill; Magdi Sami; Stanley Schmidt; Randle Storm; Miguel Zabalgoitia; John Miller; Mary Chandler; Elaine M Nasco; H Leon Greene Journal: Circulation Date: 2004-03-29 Impact factor: 29.690
Authors: Benjamin A Steinberg; Anne S Hellkamp; Yuliya Lokhnygina; Jonathan L Halperin; Günter Breithardt; Rod Passman; Graeme J Hankey; Manesh R Patel; Richard C Becker; Daniel E Singer; Werner Hacke; Scott D Berkowitz; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Jonathan P Piccini Journal: Heart Rhythm Date: 2014-05-13 Impact factor: 6.343
Authors: Victor Segura-Ibarra; Francisca E Cara; Suhong Wu; David A Iruegas-Nunez; Sufen Wang; Mauro Ferrari; Arturas Ziemys; Miguel Valderrabano; Elvin Blanco Journal: J Control Release Date: 2017-07-09 Impact factor: 9.776
Authors: Mintu P Turakhia; Peter J Blankestijn; Juan-Jesus Carrero; Catherine M Clase; Rajat Deo; Charles A Herzog; Scott E Kasner; Rod S Passman; Roberto Pecoits-Filho; Holger Reinecke; Gautam R Shroff; Wojciech Zareba; Michael Cheung; David C Wheeler; Wolfgang C Winkelmayer; Christoph Wanner Journal: Eur Heart J Date: 2018-06-21 Impact factor: 29.983
Authors: Hany A Zaki; Khalid Bashir; Haris Iftikhar; Waleed Salem; Eslam Hussein Mohamed; Helmy M Elhag; Mohamed Hendy; Ahmed Abdu O Kassem; Emad El-Din Salem; Amr Elmoheen Journal: Cureus Date: 2022-07-13